Nimer S Alkhatib (Nimer Alkhatib)

ORCID

Publication Activity (10 Years)

Years Active: 2020-2024
Publications (10 Years): 18

Top Venues

Journal of medical economics

Current medical research and opinion

American journal of cardiovascular drugs : drugs, devices, and other interventions

Expert opinion on biological therapy

University of Arizona

University of Arizona (PHD)

This page only lists publications with an associated author ORCID identifier.

Affiliation History

University of Arizona Feb 02 2020

United States

Adjunct assistant professor :: Pharmaceutical and health outcomes

Al-Zaytoonah University of Jordan Jan 01 2020

Jordan

Assistant Professor :: Pharmacy

Education History

University of Arizona

United States

PHD :: Pharmaceutical Sciences

Publications

Ivo Abraham, Matthias Calamia, Nimer S Alkhatib, Marc Pondel, Karen M MacDonald
Budget impact analysis of the novel PD-1 inhibitor toripalimab versus pembrolizumab in recurrent or metastatic nasopharyngeal carcinoma. Journal of medical economics 27 (sup3) (2024)
Nimer S Alkhatib, Eman Massad, Omar Rashdan, Wendy Max, Shiraz Halloush, Hamza Abumansour, Ala'a Alkhatib, Reema A Karasneh, Samah Al-Shatnawi, Tariq Qirim, Feras Hawari, Said Alkhatib
The economic impact of tobacco smoking and secondhand smoke exposure in Jordan: estimating the direct and indirect costs. Journal of medical economics (2024)
Ivo Abraham, Matthias Calamia, Nimer S Alkhatib, Marc Pondel, Karen M MacDonald
Budget impact analysis of the novel PD-1 inhibitor toripalimab versus pembrolizumab in recurrent or metastatic nasopharyngeal carcinoma. Journal of medical economics (2024)
Nimer S Alkhatib, Eman Massad, Omar Rashdan, Wendy Max, Shiraz Halloush, Hamza Abumansour, Ala'a Alkhatib, Reema A Karasneh, Samah Al-Shatnawi, Tariq Qirim, Feras Hawari, Said Alkhatib
The economic impact of tobacco smoking and secondhand smoke exposure in Jordan: estimating the direct and indirect costs. Journal of medical economics 27 (1) (2024)
Hala H Halawah, Nimer S Alkhatib, Abdulaali R Almutairi, Mohammad Saleh, Shiraz S Halloush, Omar Rashdan, Lama Masadh, Osama H Abusara, Ivo Abraham
Cost-efficiency analysis and expanded treatment access modeling of conversion to rituximab biosimilars from reference rituximab in Jordan. Journal of medical economics (2023)
Nimer S Alkhatib, Shiraz Halloush, Ivo Abraham
The status and preparation for the next decade of biosimilars in the Middle Eastern and North African region. Expert opinion on biological therapy (2023)
Shiraz Halloush, Abdullah A Alhifany, Nimer S Alkhatib, Abdel Qader Al Bawab, Batool Al-Qawasmeh, Esra'a Al Shawakri, Jim Koeller
Cost-effectiveness of palonosetron and dexamethasone-based triple and quadruple regimens in preventing highly emetogenic chemotherapy-induced nausea and vomiting. Current medical research and opinion 38 (4) (2022)
Dina Hamarneh, Nimer S Alkhatib, Kris Denhaerynck, Stefaan Vancayzeele, Heidi Brié, Karen M MacDonald, Ivo Abraham
Gender-stratified hierarchical modeling of patient and physician determinants of antihypertensive treatment outcomes: pooled analysis of seven prospective real-world studies with 17,044 patients. Current medical research and opinion 37 (3) (2021)
Nimer S Alkhatib, Nancy K Sweitzer, Christopher S Lee, Brian Erstad, Marion Slack, Mahdi Gharaibeh, Jason Karnes, Walter Klimecki, Kenneth Ramos, Ivo Abraham
Ex Ante Economic Evaluation of Arg389 Genetically Targeted Treatment with Bucindolol versus Empirical Treatment with Carvedilol in NYHA III/IV Heart Failure. American journal of cardiovascular drugs : drugs, devices, and other interventions 21 (2) (2021)
Nimer S Alkhatib, Ali McBride, Marion Slack, Sandipan Bhattacharjee, Brian Erstad, Kenneth Ramos, Ivo Abraham
Pricing methods in outcome-based contracting: integration analysis of the six dimensions (6 δs). Journal of medical economics 23 (11) (2020)
Nimer S Alkhatib, Ivo Abraham
The six Delta platform for outcome-based contracting for pharmaceuticals. Journal of medical economics 23 (11) (2020)
Nimer S Alkhatib, Brian Erstad, Kenneth Ramos, Ali McBride, Sandipan Bhattacharjee, Marion Slack, Ivo Abraham
Pricing methods in outcome-based contracting: δ3: reference-based pricing. Journal of medical economics 23 (11) (2020)
Nimer S Alkhatib, Kenneth Ramos, Brian Erstad, Marion Slack, Ali McBride, Sandipan Bhattacharjee, Ivo Abraham
Pricing methods in outcome-based contracting: δ1: cost effectiveness analysis and cost-utility analysis-based pricing. Journal of medical economics 23 (11) (2020)
Nimer S Alkhatib, Marion Slack, Sandipan Bhattacharjee, Brian Erstad, Kenneth Ramos, Ali McBride, Ivo Abraham
Pricing methods in outcome-based contracting: δ6: adherence-based pricing. Journal of medical economics 23 (11) (2020)
Nimer S Alkhatib, Kenneth Ramos, Brian Erstad, Marion Slack, Ali McBride, Sandipan Bhattacharjee, Ivo Abraham
Pricing methods in outcome-based contracting: δ2: willingness-to-pay-based pricing. Journal of medical economics 23 (11) (2020)
Nimer S Alkhatib, Sandipan Bhattacharjee, Ali McBride, Kenneth Ramos, Marion Slack, Brian Erstad, Ivo Abraham
Pricing methods in outcome-based contracting: δ4: safety-based pricing. Journal of medical economics 23 (11) (2020)
Nimer S Alkhatib, Diana Sun, Kris Denhaerynck, Dina Hamarneh, Yoleen Van Camp, Lorenzo Villa, Heidi Brié, Stefaan Vancayzeele, Karen M MacDonald, Ivo Abraham
Hierarchical modeling of blood pressure determinants and outcomes following valsartan treatment in hypertensive patients with known comorbidities: pooled analysis of six prospective real-world studies including 11,999 patients. Current medical research and opinion 37 (1) (2020)
Nimer S Alkhatib, Ali McBride, Sandipan Bhattacharjee, Kenneth Ramos, Brian Erstad, Marion Slack, Dean Billheimer, Ivo Abraham
Pricing methods in outcome-based contracting: δ5: risk of efficacy failure-based pricing. Journal of medical economics 23 (11) (2020)

Nimer S Alkhatib.css-eqlu8i{font-size:small;padding-left:4px;} (Nimer Alkhatib)

Publication Activity (10 Years)

Top Topics

Top Venues

Nimer S Alkhatib (Nimer Alkhatib)